Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Healthcare Biotechnology

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by lv_426on Apr 27, 2020 7:51am

89 Views

Post# 30956427

RE:RE:Inv3strr comment

Ingiboy wrote: Yes the mysterious Inv3strr. Arrived suddenly with with an extraordinary amount of knowledge about Replicel and left just as suddenly without a trace. Where oh where are you Inv3strr ? We need your detailed read on what is going on with Replicel !!

Management is under a blackout ;-)

Bullboard Posts

Three micro-cap stocks on an upswing worth riding